stars 1 stars 2 stars 3

Driven to improve patients’ lives, Byondis is an independent, fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates. Byondis’ development portfolio leverages its expertise in linker-drug (LD) technology, antibody-drug conjugation and disease biology. Byondis’ fully integrated drug development capabilities cover all stages from pre-clinical and clinical R&D, production of clinical batches of the selected product candidates and regulatory filings, which are all done in-house. The company has a dedicated team of more than 200 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands.

Byondis Questions

The Byondis annual revenue was $49.7 million in 2026.

Marieke van Gent is the Vice President Intellectual Property of Byondis.

190 people are employed at Byondis.

Byondis is based in Nijmegen, Gelderland.

The NAICS codes for Byondis are [32, 325].

The SIC codes for Byondis are [283, 28].

Top Byondis Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users